Trastuzumab Combined with Thymosin α1 in the Treatment of Senile Advanced Gastric Cancer,and the Effect of Tumor Markers and Carbohydrate Antigen
Objective:To study the effect of thymosin α1 combined with trastuzumab in the treatment of elderly patients with advanced gastric cancer and its effect on the expression of serum tumor markers.Methods:80 elderly patients with advanced gastric cancer who were admitted to the hospital from January 2017 to January 2022 were selected and divided into two groups according to the double-blind method,with 40 cases in each group.Both groups were treated with chemotherapy,the control group was treated with intravenous trastuzumab,and the observation group was treated with thymosin α1 on the basis of the control group.The efficacy,survival time,tumor marker changes,carbohydrate antigen changes and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate of control group was lower than that of observation group(x2=7.324,P＜0.05).After treatment,the 3-year and 5-year survival rates of the observation group were higher than those of the control group,and the difference was statistically significant(x2=9.899,12.288;P＜0.05),while the 1-year survival rates of the two groups were not statistically significant(x2=1.726,P＞0.05).The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and carbohydrate antigen 125(CA125)in observation group were lower than those in control group,and the differences were statistically significant(t=2.564,5.346,4.028;P＜0.05).After treatment,the incidence of adverse reactions in observation group was significantly lower than that in control group,and the difference was statistically significant(x2=4.053,P＜0.05).Conclusion:Thymosin α1 combined with trastuzumab has good effect on postoperative survival and tumor markers in elderly gastric cancer,with high safety.
TrastuzumabThymosin α1Advanced gastric cancer in the elderlyTumor markersCarbohydrate antigen
NETL
NSTL
万方数据
